All In Biotech

Drug Trial Radar · NCT06013618

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 19, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Sun Yat-Sen University Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hainan General Hospital
First posted
Aug 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an prospective study to evaluate the safety and efficacy of naxitamab monotherapy or combined with chemotherapy or combined with chemotherapy and checkpoint inhibitor in the treatment of pediatric high-risk and refractory/relapsed neuroblastoma in Sun Yat-sen University Cancer Center.

Conditions

  • Neuroblastoma

Interventions

  • Naxitamab monotherapyDrug

    Naxitamab is administered on days 1, 3, and 5

  • GM-CSFDrug

    Each treatment cycle is 28 days and is started with five days (days -4 to 0) of GM-CSF administered at 250 mcg/m2/day in advance of the start of naxitamab infusion. GM-CSF is thereafter administered at 500 mcg/m2/day on days 1 to 5.

  • IrinotecanDrug

    Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.

  • TemozolomideDrug

    Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.

  • Naxitamab in combination therapyDrug

    Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.

  • GM-CSF with combination regimenDrug

    GM-CSF 250 mcg/m2/day will be administered subcutaneously on Days 6-10.

  • SintilimabDrug

    Sintilimab was administerd with 3mg/kg (max 200mg) on day 11 every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: from start of naxitamab treatment to 1.5 years after EOT

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.